Anti-Mouse DKK1 Recombinant Antibody (JC18) (CAT#: TAB-192MZ)

Figure 1 shows the effect of anti-mouse Dkk-1 monoclonal antibody (JC18) in an intact mouse model.

Total BMD of distal femurs was significantly increased by JC18 treatment at all dose levels.

Figure 2 shows the specificity of binding of JC18 to human homologues Dkk-1, Dkk-3 and Dkk-4. JC18 showsed weak binding to human Dkk-4 and no binding to human Dkk-3 up to 5 ug/ml.

Figure 3 shows that JC18 prevented bone loss induced by estrogen deficiency in OVX mouse model.

JC18 dose-responsively increased total BMD as measured by pQCT at distal femurs by 7 to 20% compared with vehicle treatment of OVX mice. In the mice treated with JC18 at 15 mg/kg twice weekly the total BMD was not only higher than vehicle-treated OVX mice but also maintained at the sham control level, indicating that at this dose and dosing regimen JC18 completely prevented the development of osteopenia in OVX mice.